1. Home
  2. DCOY vs INM Comparison

DCOY vs INM Comparison

Compare DCOY & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$6.00

Market Cap

3.1M

Sector

Health Care

ML Signal

N/A

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$0.69

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCOY
INM
Founded
N/A
1981
Country
United States
Canada
Employees
11
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
2.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DCOY
INM
Price
$6.00
$0.69
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
14.2K
82.8K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,942,633.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.50
52 Week Low
$0.53
$0.58
52 Week High
$9.09
$7.98

Technical Indicators

Market Signals
Indicator
DCOY
INM
Relative Strength Index (RSI) 55.86 44.21
Support Level $5.40 $0.58
Resistance Level $9.09 $0.94
Average True Range (ATR) 0.66 0.05
MACD -0.28 0.01
Stochastic Oscillator 35.72 80.21

Price Performance

Historical Comparison
DCOY
INM

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Share on Social Networks: